Cartesian Therapeutics, Inc.
About
7.21USD+0.28 +4.04%
Closed • Updated at 07:28 GMT+00:00Market Cap$211.84M
Volume150.6K
Beta2.31
RSI51.35
Gross Margin-36.23%
Cartesian Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 26 2026
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
May 12 2026
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Apr 30 2026
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Mar 9 2026
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Jan 9 2026
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
Recent Videos
Using a mRNA based CAR-T for autoimmune conditions with Cartesian Therapeutics.
May 22, 2026
RNAC STOCK : POTENTIAL BREAKOUT | CARTESIAN THERAPEUTICS STOCK
Apr 13, 2026
Cartesian Therapeutics: Insider Moves & Market Shifts! #RNAC #BiotechStocks #MarketAnalysis
Apr 01, 2026
Myasthenia Gravis Treatment Without Chemo? This mRNA CAR-T Therapy Is a Game Changer
Mar 14, 2026
Community Chat
Ask AI
Try asking